The N.F. Gamaleya National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment Fund have announced the efficacy of their newly developed inoculation, the world’s first registered COVID-19 vaccine, has topped 95%, with the latter uplifting results shown 42 days after the first shot.

The evaluation was carried out among 18,794 volunteers 28 days after receiving the first dose (7 days after the second dose) of the vaccine or placebo, upon reaching the second checkpoint in line with clinical trial protocols. The analysis of this phase demonstrated a 91.4% efficacy rate for the Sputnik V vaccine.